MPNs

The MOMENTUM trial continues to show positive results for momelotinib fro the treatment of anemic myelofibrosis.

Phase 1 data demonstrate that the combination of selinexor and ruxolitinib has the potential to be a novel first-line treatment for myelofibrosis patients, according to Haris Ali, MD.

Joseph M. Scandura, MD, PhD, provides an overview on the research of pelabresib which will be discussed at the 2022 American Society of Hematology Annual Meeting.

During a Targeted Oncology case-based roundtable event, Kristen M. Pettit, MD, discussed with participants the case of a patient with high-risk primary myelofibrosis and significant cytopenias.

In an interview with Targeted Oncology, Srdan Verstovsek, MD, discussed the current MPN treatment landscape and where the field is shifting.

During a Targeted Oncology case-based roundtable event, Jeanne M. Palmer, MD, discussed with participants how the approval of pacritinib for patients with myelofibrosis affects their treatment approach.

During a Targeted Oncology case-based roundtable event, Raajit K. Rampal, MD, PhD, discussed recommendations and data on the use of JAK inhibitors to treat patients with myelofibrosis.

During a Targeted Oncology case-based roundtable event, Pankit Vachhani, MD, discussed with participants how to assess risk and begin treatment for myelofibrosis. This is the second of 2 articles based on this event.

At the 14th International Congress on Myeloproliferative Neoplasms, research into the case of dizygotic twins with essential thrombocythemia won the Best overall Abstract Award for concluding how their rare stem cell disorder was passed between both twins.

At the 14th International Congress on Myeloproliferative Neoplasms, Srdan Verstovsek, MD, PhD, reviewed the research supporting the optimal use of JAK inhibitors in patients with myelofibrosis.

During a presentation at the 14th Annual International Congress on Myeloproliferative Neoplasms, Naveen Pemmaraju, MD, discussed the current agents being examined for MPNs.

Srdan Verstovsek, MD, PhD, discusses the increased thrombotic risk and management for patients with essential thrombocythemia.

Raajit Rampal, MD, PhD, discusses unmet needs for therapies to treat patients with myelofibrosis.

During a Targeted Oncology case-based roundtable event, Pankit Vachhani, MD, discussed with participants how they would diagnose a patient who potentially has primary myelofibrosis.

During the NCCN 2022 Annual Congress: Hematologic Malignancies, Aaron Gerds, MD, explained risk stratification in patients with polycythemia vera, frontline treatment options, and outcomes for the patient population based on findings from clinical trials.

During a live virtual event, John O. Mascarenhas, MD, discussed with participants the data supporting the use of pacritinib for patients with myelofibrosis. This is the second of 2 articles based on this event.

Ellen K. Ritchie, MD, discuss the case of a 68-year-old man with high-risk myelofibrosis during a case-based roundtable event.

Early results from the phase 2a MYLOX-1 study show a reduction of collagen fibrosis of the bone marrow in patients with myelofibrosis on the LOXL2 inhibitor GB2064.

Srdan Verstovsek, MD, PhD, highlights what future research in myeloproliferative neoplasms looks to examine.

Haris Ali, MD, explored the potential role of disease-modifying agents on transplant indications in this setting during the 10th Annual Meeting of the Society of Hematologic Oncology

Srdan Verstovsek, MD, PhD, highlighted recent advancements in developing novel therapeutic strategies for myelofibrosis during SOHO 2022.

Currently, there are few treatment options for patients with polycythemia vera that can help to control hematocrit levels and reduce the need for phlebotomy and the incidence of thrombosis.

During a Targeted Oncology case-based roundtable event, Andrew Kuykendall, MD, discussed the treatment options for a patient with myelofibrosis based on factors including platelet count.

During a live virtual event, John O. Mascarenhas, MD, discussed the PERSIST-1 and PERSIST-2 trials of pacritinib for patients with myelofibrosis with lower platelet counts.

Srdan Verstovsek, MD, PhD, discusses some of the best practices to try and prevent thrombosis in patients with polycythemia vera.

Srdan Verstovsek, MD, PhD, discusses why the first ever FDA approved interferon drug ropeginterferon alfa-2b-njft is important for adult patients with polycythemia vera.

In the interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the FDA approval of pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. He also discussed the FIGHT-203 trial, and possibilities for pemigatinib in the future.

Following promising preclinical data, the phase 1 IMproveMF trial in myelofibrosis doses its first patient with imetelstat and ruxolitinib.

Results from the MANIFEST study of pelabresib and ruxolitinib in myelfibrosis are positive. The phase MANIFEST-2 study continue to explored the combination in JAK inhibitor–naïve patients with myelofibrosis.